Literature DB >> 12901459

Tuberculosis outbreak investigation of a U.S. Navy amphibious ship crew and the Marine expeditionary unit aboard, 1998.

James E Lamar1, Mark A Malakooti.   

Abstract

A Marine deployed aboard a U.S. Navy amphibious ship had smear-positive, cavitary pulmonary tuberculosis (TB). Contact investigation ultimately found 21 active cases of TB among sailors and Marines who were aboard the affected ship. Approximately 3 months lapsed between onset of the source patient's illness and appropriate diagnosis and treatment. During the contact investigation, 3,338 persons received tuberculin skin tests and 712 were identified as new latent tuberculosis infection cases. Four persons diagnosed with latent tuberculosis infection developed active TB because of poor compliance with treatment. After personnel disembarked from the ship, persistent efforts to identify persons with active disease and latent infections were successful in controlling further spread of tuberculosis in military units and local communities. The Mycobacterium tuberculosis bacteria isolated from the source patient and 16 of the other active cases were susceptible to all drugs commonly used to treat TB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901459

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  9 in total

1.  The importance of militaries from developing countries in global infectious disease surveillance.

Authors:  Jean-Paul Chretien; David L Blazes; Rodney L Coldren; Michael D Lewis; Jariyanart Gaywee; Khunakorn Kana; Narongrid Sirisopana; Victor Vallejos; Carmen C Mundaca; Silvia Montano; Gregory J Martin; Joel C Gaydos
Journal:  Bull World Health Organ       Date:  2007-03       Impact factor: 9.408

Review 2.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  Challenges in Obtaining Estimates of the Risk of Tuberculosis Infection During Overseas Deployment.

Authors:  James D Mancuso; Mia Geurts
Journal:  Am J Trop Med Hyg       Date:  2015-09-28       Impact factor: 2.345

4.  Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits.

Authors:  Jason M Lempp; Margan J Zajdowicz; Arlene L Hankinson; Sean R Toney; Lisa W Keep; James D Mancuso; Gerald H Mazurek
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

5.  Polymorphisms in Toll-Like Receptor 10 and Tuberculosis Susceptibility: Evidence from Three Independent Series.

Authors:  Yu Wang; Miao-Miao Zhang; Wei-Wei Huang; Shou-Quan Wu; Ming-Gui Wang; Xiao-Yan Tang; Andrew J Sandford; Jian-Qing He
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

6.  The Infectivity of Pulmonary Tuberculosis in Korean Army Units: Evidence from Outbreak Investigations.

Authors:  Chang Gyo Yoon; Dong Yoon Kang; Jaehun Jung; Soo Yon Oh; Jin Beom Lee; Mi Hyun Kim; Younsuk Seo; Hee Jin Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2019-05-31

Review 7.  Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.

Authors:  Laurent Abel; Jacques Fellay; David W Haas; Erwin Schurr; Geetha Srikrishna; Michael Urbanowski; Nimisha Chaturvedi; Sudha Srinivasan; Daniel H Johnson; William R Bishai
Journal:  Lancet Infect Dis       Date:  2017-10-27       Impact factor: 25.071

8.  Frequency of latent and smear positive tuberculosis in chronic psychotic disorders.

Authors:  Hannan Ebrahimi; Mohammad Ja'far Modabbernia; Alieh Mohammadi; Sina Khajeh Jahromi; Misa Naghdipour; Hossein Ebrahimi
Journal:  Iran J Psychiatry       Date:  2013-03

Review 9.  Infections in confined spaces: cruise ships, military barracks, and college dormitories.

Authors:  Vivek Kak
Journal:  Infect Dis Clin North Am       Date:  2007-09       Impact factor: 5.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.